CJC-1295 vs Ipamorelin: What Sets Them Apart?
CJC-1295 and ipamorelin are both growth hormone secretagogues, but they work through completely different receptor pathways. Understanding this distinction explains why they're so frequently combined in research protocols.
The Core Difference
CJC-1295
GHRH analogue — binds to GHRH receptors on the pituitary. Amplifies the "signal" to produce GH. Mimics the hypothalamus's own signal. Like turning up the volume on the instruction.
Ipamorelin
Ghrelin receptor agonist — binds to GHS-R1a on the pituitary. Triggers the actual release of stored GH. Works at the pituitary level. Like pressing the release button.
Why Combine Them?
When used together, CJC-1295 amplifies the GH production signal from the hypothalamus while ipamorelin triggers the release from the pituitary. Two distinct receptor pathways, working in coordination, produce a more robust and physiologic GH secretion profile than either compound alone.
Key Differences at a Glance
Selectivity
Ipamorelin wins. It's one of the most selective GH secretagogues — minimal impact on cortisol, prolactin, or ACTH. CJC-1295 has a broader hormonal footprint.
Half-Life
CJC-1295 (no DAC) has a half-life of ~30 minutes, producing discrete GH pulses. The DAC version extends this to days. Ipamorelin has a similar short half-life (~2 hours), making both suited for pulsatile dosing.
Standalone vs Combination
Either can be used alone, but the combination is considered more effective in research. CJC-1295 alone may produce a less robust GH pulse. Ipamorelin alone works well but benefits from the amplification CJC-1295 provides.
Shop Ipamorelin → · CJC+Ipa blend currently sold out — join our newsletter for restock alerts. · Reconstitution Guide →
All products sold by Tidal Peptides are for research use only. Not for human consumption.